Pharmaceuticals

Familial Amyloid Polyneuropathy Market Anticipated to Record Steady Gains, Advancing to $2.43 Billion by 2030

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the familial amyloid polyneuropathy market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Familial Amyloid Polyneuropathy Market from 2026 to 2030?

The familial amyloid polyneuropathy market size has shown substantial expansion in recent years. It is forecast to grow from $1.65 billion in 2025 to $1.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. This past growth can be ascribed to several factors, including advancements in rare disease diagnosis, increased genetic disorder awareness, developments in transplant medicine, ongoing neurology research, and the wider adoption of supportive care.

The familial amyloid polyneuropathy market is poised for significant expansion in the upcoming years. It is projected to reach $2.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This anticipated growth throughout the forecast period stems from factors such as innovation in gene therapy, the availability of early genetic testing, increased funding for rare diseases, the adoption of precision medicine, and the growth of specialty pharmacies. Furthermore, key trends in this period include the rising adoption of TTR stabilizers, the broadening scope of gene silencing therapies, an increase in genetic screening, a greater focus on rare disease treatments, and the development of more specialty care centers.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24532&type=smp

What Drivers Are Affecting Demand In The Familial Amyloid Polyneuropathy Market?

The increasing emphasis on gene therapy is projected to drive the expansion of the familial amyloid polyneuropathy market in the future. Gene therapy is a therapeutic approach designed to modify or substitute faulty genes to address the fundamental cause of diseases. It is gaining traction because it targets and repairs defective genes, offering lasting or permanent cures rather than merely relieving symptoms. For familial amyloid polyneuropathy, gene therapy aims to correct or silence the malfunctioning transthyretin (TTR) gene, thereby preventing the formation of harmful amyloid proteins. This action helps diminish amyloid deposits, slowing down disease progression and preserving nerve function. For instance, in July 2023, information from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, indicated that 247 gene therapies were in Phase II at the end of the first quarter of 2023, a figure that increased by 5% to reach 260 by the close of the second quarter. Thus, the growing attention on gene therapy is stimulating the growth of the familial amyloid polyneuropathy market.

Which Segment Groups Are Influencing The Familial Amyloid Polyneuropathy Market?

The familial amyloid polyneuropathy market covered in this report is segmented –

1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment

2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis

3) By Patient Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran

2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy

3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling

4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants

5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment

Which Market Trends Are Opening Growth Opportunities In The Familial Amyloid Polyneuropathy Market?

Companies operating within the familial amyloid polyneuropathy market are prioritizing the development of advanced therapeutic solutions, such as RNA interference (RNAi) therapeutics, with the aim of slowing disease progression and improving patient outcomes. RNA interference (RNAi) therapeutics represent cutting-edge treatments that silence disease-causing genes by specifically targeting their messenger RNA (mRNA). This method effectively blocks the production of harmful proteins, addressing genetic diseases at their source. For example, in March 2025, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, introduced AMVUTTRA (vutrisiran), which had previously received approval from the Food and Drug Administration (FDA) for the treatment of cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. It is administered as four subcutaneous doses per year and is designed to treat both ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN). By reducing the production of the transthyretin (TTR) protein, identified as the root cause of the disease, it significantly diminishes cardiovascular mortality, hospitalizations, and urgent heart failure visits, as demonstrated during the HELIOS-B Phase 3 clinical trial.

Who Are The Prominent Global Companies Shaping The Familial Amyloid Polyneuropathy Market Landscape?

Major companies operating in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Precision BioSciences Inc., Creative Biolabs, Stanford Health Care, Duke University Health System, YolTech Therapeutics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/familial-amyloid-polyneuropathy-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Familial Amyloid Polyneuropathy Market?

North America was the largest region in the familial amyloid polyneuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial amyloid polyneuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Familial Amyloid Polyneuropathy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24532&type=smp

Browse Through More Reports Similar to the Global Familial Amyloid Polyneuropathy Market 2026, By The Business Research Company

Peripheral Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Diabetic Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795